FDC LIMITED
FDC · Pharma · NSE
₹366
Current Market Price
Fair Value (DCF)
₹677
Margin of Safety
+84.8%
Updated just now
YieldIQ Score
72/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
60%
ROE
—
Debt/Equity
0.01
WACC
9.7%
Market Cap
₹5,961 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.3%
Return on capital employed
EV / EBITDA
20.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
96.8×
EBIT covers interest
Current Ratio
3.01×
Short-term liquidity
Asset Turnover
0.78×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹366.15
Bear case
₹365.24
MoS -0.2%
Base case
₹676.52
MoS +45.9%
Bull case
₹823.79
MoS +55.6%
Ratio Trends
FDC · last 8 annual periods
ROE
11.7%
ROCE
18.0%
Operating Margin
—
Debt / Equity
0.01×
PE
136.1×
EV / EBITDA
13.8×
Historical Financials
FDC · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1333 Cr | ₹1528 Cr | ₹435 Cr | ₹462 Cr | ₹2108 Cr | +12.1% |
| EBITDA | — | ₹329 Cr | ₹300 Cr | ₹440 Cr | ₹415 Cr | +5.9% |
| EBIT | ₹391 Cr | ₹292 Cr | ₹46.3 Cr | ₹66.2 Cr | — | -35.9% |
| PAT | ₹301 Cr | ₹216 Cr | ₹30.7 Cr | ₹46.3 Cr | ₹267 Cr | -3.0% |
| EPS (diluted) | ₹17.72 | ₹12.81 | ₹1.85 | ₹2.84 | — | -36.7% |
| CFO | ₹207 Cr | ₹162 Cr | ₹155 Cr | ₹221 Cr | ₹318 Cr | +11.3% |
| CapEx | — | — | — | — | ₹-96.7 Cr | — |
| FCF | — | — | — | — | ₹221 Cr | +0.0% |
| Total Assets | — | ₹2270 Cr | ₹2343 Cr | ₹2468 Cr | ₹2714 Cr | +4.6% |
| Total Debt | — | — | ₹0.1 Cr | ₹0.0 Cr | ₹21.2 Cr | +308.7% |
| Shareholders' Equity | — | — | ₹1982 Cr | ₹2097 Cr | ₹2281 Cr | +3.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
FDC vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| AARTIPHARM AARTIPHARM | — | — | Pending | 13.7% | — |
| SUVEN SUVEN | — | — | Pending | — | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Above Fair Value | 3.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for FDC in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. FDC LIMITED (FDC.NS) trades at 366.15 vs a model fair value of 676.52, a gap of 84.8%. Piotroski F-score: 5/9. Moat label: Wide. Revenue ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of FDC →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for FDC →
Compare
Head-to-head with peers
Compare FDC side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse FDCNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.